François-Clément B.
- Country
- France
- Department
- N/A
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Phase III Randomized Double‑Blind Study of Alpelisib Plus Trastuzumab and Pertuzumab Maintenance Therapy in HER2‑Positive Advanced Breast Cancer with PIK3CA Mutation
- TAILORswitch (PADA-2): ctDNA‑guided switch to camizestrant plus abemaciclib in ER‑positive HER2‑negative metastatic breast cancer
Data & Insights
Has run more than one trial at 365 of 648 partner sites.
Specializations
Breast Cancer Molecular Subtypes
The investigator specializes in various molecular subtypes of breast cancer, with particular focus on hormone receptor-positive (HR+) and HER2-negative disease states. Their research extends to triple-negative breast cancer (TNBC) and cases with specific genetic mutations like PIK3CA and GATA3.
- ER+/HER2- advanced breast cancer
- Triple-negative breast cancer management
- Mutation-specific therapeutic approaches
Biomarker Research
Their work encompasses the study of various biomarkers in breast cancer, including circulating tumor DNA (ctDNA) for early detection of disease recurrence. The investigator focuses on ESR1 mutations and their implications for treatment resistance.
- Molecular relapse detection
- Circulating biomarker analysis
- Genetic mutation tracking
Treatment Innovation
The investigator explores novel therapeutic combinations including CDK4/6 inhibitors, endocrine therapy, and innovative approaches such as immunotherapy. Their research covers both early-stage and metastatic disease settings.
- Targeted therapy combinations
- Endocrine resistance management
- Advanced disease treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.